Cellosaurus cell line NK-92 (CVCL

Cellosaurus NK-92 (CVCL_2142)

[Text version]

Cell line name

NK-92

Synonyms

NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK

Accession

CVCL_2142

Resource Identification Initiative

To cite this cell line use: NK-92 (RRID:CVCL_2142)

Comments

Group: Patented cell line.
Part of: LL-100 blood cancer cell line panel.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670.
Population: Caucasian.
Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections.
Characteristics: IL2 dependent.
Characteristics: Does not express FCGR3A/CD16.
Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ=ACC-488).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Genomics; Whole exome sequencing.
Omics: Transcriptomics; Microarray.
Omics: Transcriptomics; RNAseq.
Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: Natural killer cell; CL=CL_0000623.

Sequence variations

Mutation; HGNC; HGNC:882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800).

HLA typing

Source: DSMZCellDive=ACC-488

Class I
HLA-A	A*03:01:01,11:01:01
HLA-B	B*07:02:01,44:03:01
HLA-C	C*07:02:01,16:01:01
Class II
HLA-DP	DPA1*01:03:01,01:03:01
HLA-DQ	DQB1*06:02:01,06:02:01

Disease

Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy

Children:

CVCL_W733 (GFP-CD16-F/F.NK-92)	CVCL_W734 (GFP-CD16-V/V.NK-92)	CVCL_IM23 (haNK)
CVCL_VN54 (laNK)	CVCL_C7GQ (NK-92 clone 1)	CVCL_C7GR (NK-92 clone 2)
CVCL_VN56 (NK-92 GFP)	CVCL_VN57 (NK-92.26.5)	CVCL_U271 (NK-92CI)
CVCL_3755 (NK-92MI)	CVCL_B5ZF (NK92-41BB)	CVCL_B5ZE (NK92-CD16)
CVCL_V429 (NoGFP-CD16.NK92)	CVCL_B3PC (TR-IL2-NK-92)	CVCL_E1A9 (Ubigene NK-92 FCER1G KO)

Sex of cell

Male

Age at sampling

50Y

Category

Cancer cell line

STR profile

Source(s): ATCC=CRL-2407; DSMZ=ACC-488; Technion Genomics Center

Markers:

Amelogenin	X,Y
CSF1PO	11,12
D1S1656	12,14
D2S441	19,20
D2S1338	19,20
D3S1358	15
D5S818	12,13
D7S820	10,11
D8S1179	12,15
D10S1248	14,15
D12S391	19,22
D13S317	9,12
D16S539	11,12
D18S51	12,17
D19S433	14,15
D21S11	31.2,32
D22S1045	12,17
DYS391	12
FGA	20,22
Penta D	10,12
Penta E	12
TH01	6,9.3
TPOX	8
vWA	16,18 (DSMZ=ACC-488; Technion Genomics Center) 18 (ATCC=CRL-2407)

Web pages

Info; -; -; https://web.archive.org/web/20211125114549/http://www2.kumc.edu/soalab/LabLinks/cell%20lines/nk92.htm
Info; ATCC; -; https://www.atcc.org/en/support/technical-support/faqs/growth-and-morphology-of-nk-92-cells
Info; ClinicalTrials.gov; NCT00900809; https://clinicaltrials.gov/study/NCT00900809
Info; ClinicalTrials.gov; NCT00990717; https://clinicaltrials.gov/study/NCT00990717
Info; ClinicalTrials.gov; NCT02465957; https://clinicaltrials.gov/study/NCT02465957
Info; Wikipedia; -; https://en.wikipedia.org/wiki/NK-92
Provider; Brink Biologics; -; https://brinkbiologics.com/platform/

Publications

PubMed=8152260
Jian-Hong Gong, Guitta Maki, Hans-Georg Klingemann;
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Leukemia 8:652-658(1994)

PubMed=9118301
Hans-Georg Klingemann, Elaine Wong, Guitta Maki;
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Biol. Blood Marrow Transplant. 2:68-75(1996)

PubMed=9573023; DOI=10.1182/blood.V91.10.3850
Shigeki Nagashima, Robbie Mailliard, Yoshiro Kashii, Torsten E. Reichert, Ronald Bruce Herberman, Paul Robbins, Theresa L. Whiteside;
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Blood 91:3850-3861(1998)

PubMed=10365666; DOI=10.1089/10430349950018030
Ying K. Tam, Guitta Maki, Blythe Miyagawa, Burkhard Hennemann, Torsten Tonn, Hans-Georg Klingemann;
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

PubMed=10803505; DOI=10.1038/sj.leu.2401778
Hans Gunther Drexler, Yoshinobu Matsuo;
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Leukemia 14:777-782(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Hans Gunther Drexler;
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=11454312; DOI=10.1089/152581601750288975
Guitta Maki, Hans-Georg Klingemann, Jeffrey A. Martinson, Ying K. Tam;
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
J. Hematother. Stem Cell Res. 10:369-383(2001)

PubMed=12850795; DOI=10.1080/14653240310001523
Ying K. Tam, Jeffrey A. Martinson, K. Doligosa, Hans-Georg Klingemann;
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Cytotherapy 5:259-272(2003)

PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954
Angen Liu, Tetsuya Takakuwa, Wen-Juan Luo, Shigeki Fujita, Katsuyuki Aozasa;
Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Cancer Sci. 97:605-610(2006)

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392; PMCID=PMC2810560
Liat Binyamin, R. Katherine Alpaugh, Tracey L. Hughes, Charles T. Lutz, Kerry S. Campbell, Louis M. Weiner;
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J. Immunol. 180:6392-6401(2008)

PubMed=19194464; DOI=10.1038/leu.2009.3
Javeed Iqbal, Can Kucuk, Ronald J. Deleeuw, Gopesh Srivastava, Wayne Tam, Hui-Min Geng, David L. Klinkebiel, Judith K. Christman, Kavita N. Patel, K. Cao, L. Shen ...Show all 18 authors... , Karen Dybkaer, Ivy F.L. Tsui, Hesham H. Ali, N. Shimizu, Wing Yan Au, Wan L. Lam, Wing-Chung Chan; Show fewer authors
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Leukemia 23:1139-1151(2009)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Cord C. Uphoff, Sabine A. Denkmann, Klaus G. Steube, Hans Gunther Drexler;
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255
Javeed Iqbal, Dennis D. Weisenburger, Aparajita Chowdhury, Ming-Ying Tsai, Gopesh Srivastava, Timothy Charles Greiner, Can Kucuk, Karen E. Deffenbacher, Julie Marie Vose, L. Smith, Wing Yan Au ...Show all 22 authors... , Shigeo Nakamura, Masao Seto, Jan Delabie, Francoise Berger, Florence Loong, Young-Hyeh Ko, Ivy Sng, X. Liu, Thomas P. Loughran Jr., James Olen Armitage, Wing-Chung Chan; Show fewer authors
International Peripheral T-cell Lymphoma Project
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Leukemia 25:348-358(2011)

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010
Alfred Schnueriger, Roger Grau, Peter Sondermann, Thomas Schreitmueller, Stefan Marti, Marcel Zocher;
Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
Mol. Immunol. 48:1512-1517(2011)

PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911
Can Kucuk, Bei Jiang, Xiao-Zhou Hu, Wen-Yan Zhang, John K.C. Chan, Wen-Ming Xiao, Nathan Lack, Can Alkan, John C. Williams, Kendra N. Avery, Pynar Kavak ...Show all 28 authors... , Anna Scuto, Emel Sen, Philippe Gaulard, Louis Michael Staudt, Javeed Iqbal, Wei-Wei Zhang, Adam Cornish, Qiang Gong, Qun-Pei Yang, Hong Sun, Francesco Annibale d'Amore, Sirpa Leppa, Wei-Ping Liu, Kai Fu, Laurence de Leval, Timothy W. McKeithan, Wing-Chung Chan; Show fewer authors
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
Nat. Commun. 6:6025.1-6025.12(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x; PMCID=PMC11029582
Garnet Suck, Marcus Odendahl, Paulina Nowakowska, Christian Seidl, Winfried S. Wels, Hans-Georg Klingemann, Torsten Tonn;
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015; PMCID=PMC6345623
Justin Tyme Gunesch, Laura S. Angelo, Sanjana Mahapatra, Raquel Payzant Deering, Johanna E. Kowalko, Patrick Sleiman, John W. Tobias, Linda Monaco-Shawver, Jordan Scott Orange, Emily M. Mace;
Genome-wide analyses and functional profiling of human NK cell lines.
Mol. Immunol. 115:64-75(2019)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2; PMCID=PMC6534912
Hyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, Injung Hwang, Hyun Tak Jin, Young Chul Sung, Ki-Seong Eom, Sae Won Kim;
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
J. Immunother. Cancer 7:138.1-138.17(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646
Hilmar Quentmeier, Claudia Pommerenke, Wilhelm Gerhard Dirks, Sonja Eberth, Max Koeppel, Roderick A.F. MacLeod, Stefan Nagel, Klaus G. Steube, Cord C. Uphoff, Hans Gunther Drexler;
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218.1-8218.14(2019)

PubMed=34349345; DOI=10.1007/s10616-021-00476-1; PMCID=PMC8319282
Hui Zhao, Zhen-Long Zhou, Guang-Meng Li, Gang Liu, Shu-Yin Lin, Wei Chen, Sheng Xiong;
An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
Cytotechnology 73:539-553(2021)

PubMed=36610812; DOI=10.1016/j.jcyt.2022.12.003
Hans-Georg Klingemann;
The NK-92 cell line -- 30 years later: its impact on natural killer cell research and treatment of cancer.
Cytotherapy 25:451-457(2023)

Cross-references

Cell line collections (Providers)

AddexBio; C0003026/NA - Discontinued
ATCC; CRL-2407
BCRC; 60414 - Discontinued
CCTCC; GDC0052
DSMZ; ACC-488

Cell line databases/resources

CLO; CLO_0008177
CCRID; 4201HUM-CCTCC00052
Cell_Model_Passport; SIDM01143
DSMZCellDive; ACC-488
IPD-IMGT/HLA; 13674
Lonza; 1093

Anatomy/cell type resources

BTO; BTO_0003287

Biological sample resources

BioSample; SAMN03471836

Encyclopedic resources

Wikidata; Q17149636

Experimental variables resources

EFO; EFO_0022517

Gene expression databases

ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM472001

Polymorphism and mutation databases

Cosmic; 1534874
Cosmic; 1542071
Cosmic; 2025326
Cosmic; 2390215
Cosmic; 2785204

Entry history

Entry creation

04-Apr-2012

Last entry update

14-Aug-2025

Version number